---
schema_version: "secwatch.filing_event.v1"
accession: "0001619856-24-000063"
form_type: "8-K"
ticker: "CRBU"
cik: "0001619856"
company_name: "Caribou Biosciences, Inc."
filed_at: "2024-08-06T23:59:59+00:00"
generated_at: "2026-05-31T12:17:53.534271+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Caribou Q2 net loss $37.7M; extends cash runway to H2 2026 after 12% workforce cut

## Summary
- Net loss $37.7M in Q2 2024 vs $29.5M in Q2 2023; cash & equivalents $311.8M at June 30, down from $372.4M.
- Discontinued preclinical CAR-NK platform; reduced workforce ~12% to extend cash runway into H2 2026.
- CB-010 ANTLER enrolling ~20 2L LBCL and ~10 prior CD19 relapsed patients; initial data expected H1 2025.
- CB-011 CaMMouflage dose-escalation data for r/r multiple myeloma planned by year-end 2024.
- Appointed autoimmune expert Terri Laufer, MD to SAB; CB-010 GALLOP lupus trial initiation expected by year-end 2024.

## SEC filing metadata
- accession: 0001619856-24-000063
- form_type: 8-K
- ticker: CRBU
- cik: 0001619856
- company_name: Caribou Biosciences, Inc.
- filed_at: 2024-08-06T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1619856/000161985624000063/0001619856-24-000063-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1619856/000161985624000063/crbu-20240806.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001619856-24-000063
- JSON: https://secwatch.observer/filing/0001619856-24-000063.json
- Plain text: https://secwatch.observer/filing/0001619856-24-000063.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.